Table 2 Regulatory agency-approved mRNA vaccines
Brand (Generic) name | Drug name | Originator company | Approval year | Regulatory agency | Disease | Delivery platform | Route | Target-based actions |
|---|---|---|---|---|---|---|---|---|
Comirnaty (Tozinameran) | BNT-162b2 | BioNTech SE | 2020 | EMA | SARS-COV-2 | LNP | i.m. injection | COVID19 spike glycoprotein modulator |
2020 | HC | |||||||
2020 | MHRA | |||||||
2021 | FDA | |||||||
Comirnaty Original/Omicron BA.4–5 (Tozinameran/Famtozinameran) | BNT-162b2 bivalent (WT/OMI BA.4/BA.5) | 2022 | EMA | SARS-COV-2 | LNP | i.m. injection | COVID19 spike glycoprotein modulator | |
2022 | HC | |||||||
2022 | MHRA | |||||||
Spikevax (Elasomeran) | mRNA-1273 | Moderna | 2020 | HC | SARS-COV-2 | LNP | i.m. injection | COVID19 spike glycoprotein modulator |
2021 | EMA | |||||||
2021 | MHRA | |||||||
2022 | FDA | |||||||
Spikevax Bivalent Original/Omicron BA.1 (Elasomeran/Imelasomeran) | mRNA-1273.214 | 2022 | EMA | SARS-COV-2 | LNP | i.m. injection | COVID19 spike glycoprotein modulator | |
2022 | MHRA | |||||||
Spikevax Bivalent Original/Omicron BA.4–5 (Elasomeran/Davesomeran) | mRNA-1273 containing SARS-CoV-2 omicron-specific bivalent (BA.4/BA.5) | 2022 | EMA | SARS-COV-2 | LNP | i.m. injection | COVID19 spike glycoprotein modulator | |
2023 | SMC |